NeOnc Technologies Holdings is trading 9.3% down now at $4.98 after a sharp multi-session rally.

  • The stock gained 31.46% on August 14, 16.35% on August 17, and 12.63% on August 18.
  • The advance followed positive Phase 2a NEO100 glioma results, including 48.9% six-month progression-free survival versus a 20% benchmark.
  • No stronger company-specific announcement explaining the August 19 decline was identified.